AKT1 and coronary artery disorder: Since tanshinone IIA has been safely used in clinical practice, particularly in patients with ischemic heart diseases in Asia, the concept of tanshinone postconditioning by the PI3K/Akt-mPTP pathway may represent a practical solution to reduce ischemia-reperfusion injury as an adjuvant to current reperfusion strategies.